Omkar Pharmachem Ltd (OMKARPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Omkar Pharmachem Ltd on NSE and BSE, with an AI summary of each filing.
Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Omkar Pharmachem Ltd has informed ....
Intimation · 14 Nov 2026, 5:30 am
Omkar Pharmachem Board Meeting Scheduled for 14th Nov'26 to Consider Q2 Results Omkar Pharmachem Limited has scheduled a Board of Directors meeting on 14th Nov'26 to consider, approve, and record the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the insider trading window for designated persons and their immediate relatives remains closed until 16th Nov'26.
Dear Sir/Ma''am, Please find Voting Results of 31st AGM along with Consolidated Scrutinizer Report.
Annual General Meeting · 01 Oct 2026, 6:36 pm
Dear Sir/Ma''am, Please find Proceeding of 31st AGM & Reporting Under Reg. 30 of SEBI(LODR) Regulation, 2015
Annual General Meeting · 30 Sept 2026, 6:20 pm
Dear Sir, Please find intimation under regulation 42 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015
Others · 02 Sept 2026, 4:37 pm
31st Annual Report of the company along with Notice of AGM for the Financial year 2025-26
Others (Uncategorized) · 02 Sept 2026, 4:31 pm
Pursuant to Regulation 30 of SEBI( Listing Obligations and Disclosures requirements) Regulations, 2015, Please find attached herewith the Notice convening 31st Annual General Meeting of the Company
Annual General Meeting · 02 Sept 2026, 4:16 pm
Outcome of the Board Meeting held on 31st August, 2026
Others (Uncategorized) · 31 Aug 2026, 9:57 pm
Omkar Pharmachem Sets AGM Date and Board Meeting Outcome Omkar Pharmachem (Scrip: 532167) announced its 31st Annual General Meeting will be held on 30th Sep'26. The board, in its meeting on 31st Aug'26, approved the Director's report for the financial year ended 31st Mar'26. The board also considered material related party transactions and appointed M/s Maulik Bhavsar & Associates as the scrutinizer for the AGM voting process. The board meeting concluded at 04:15 P.M.
Dear Sir, Pursuant to provisions of Reg. 33 of SEBI (LODR)Regulations, 2015, please find Unaudited Financial Results for the Quarter ended on 30.06.2026
Financial Result · 13 Aug 2026, 9:52 pm
Omkar Pharmachem Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 9.0 (-33.3% YoY | +0.0% QoQ) ■ EBITDA: -1.0 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -10.7 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -1.0 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.01 (Profit to Loss YoY | Profit to Loss QoQ)
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on 13 August, ....
Outcome · 13 Aug 2026, 9:46 pm
Omkar Pharmachem Reports Q1 FY27 Net Loss on Lower Income Omkar Pharmachem reported a net loss of ₹1.00 lakh for Q1 FY27, a significant decline from a profit of ₹2.66 lakh YoY and ₹1.50 lakh QoQ. The loss was driven by a 33% YoY drop in total income to ₹9.00 lakh. Total expenses remained steady YoY at ₹10.00 lakh. Consequently, the company posted a pre-tax loss of ₹1.00 lakh compared to a pre-tax profit of ₹3.58 lakh in Q1 FY26. Diluted EPS for the quarter was negative at ₹(0.0099).
Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Unaudited Financial result ....
Intimation · 13 Aug 2026, 5:30 am
Omkar Pharmachem Board Meeting to Approve Q1FY27 Financial Results Omkar Pharmachem (BSE: 532167) has scheduled a Board of Directors meeting on 13 Aug'26 to consider and approve its unaudited financial results for the quarter ended 30 Jun'26. The company also confirmed that the trading window for designated persons will remain closed until 15 Aug'26.
Newspaper Advertisment regarding special Window
Others (Uncategorized) · 18 Jul 2026, 11:52 pm
Omkar Pharmachem Opens Window for Dematerialization of Physical Shares Omkar Pharmachem Ltd. announced it has opened a special window for the transfer and dematerialization of physical shares. The move complies with a SEBI circular (HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026) dated 30-Jan-'26. The company published newspaper advertisements on 18-Jul-'26 in both English and vernacular languages to inform shareholders of this facility. This action aims to improve liquidity and ease of trading for holders of physical share certificates.
Dear Sir/Ma''am, Please find Financial Results for the quarter and year ended 31.03.2026
Financial Result · 30 May 2026, 11:19 pm
Omkar Pharmachem Reports Q4 & FY26 Results, Net Profit Declines YoY Omkar Pharmachem reported FY26 net profit of ₹12.18 lakh, a 39.4% YoY decline from ₹20.09 lakh. Total income for FY26 decreased by 12.9% YoY to ₹47.24 lakh. For Q4 FY26, the company recorded a profit of ₹1.50 lakh, a significant turnaround from a loss of ₹2.15 lakh in Q4 FY25, but a 49.2% QoQ decline. Total Q4 income was ₹9.30 lakh, down 31.1% YoY. The firm also reported a substantial non-current investment increase to ₹3638.43 lakh from ₹930.00 lakh YoY.
Dear Sir, Please find Outcome of the Board Meeting held on 30 May, 2026 of Omkar Pharmachem Limited
Outcome · 30 May 2026, 11:13 pm
Omkar Pharmachem Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 9.0 (-33.3% YoY | -14.3% QoQ) ■ EBITDA: 1.7 (-73.9% YoY | -57.2% QoQ) ■ EBITDA Margin (%): 19.2 (-2981 bps YoY | -1925 bps QoQ) ■ PAT: 1.5 (Loss to Profit YoY | -49.2% QoQ) ■ EPS (INR): 26.9 (Loss to Profit YoY | +91621.5% QoQ)
Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Omkar Pharmachem Ltd. has ....
Intimation · 30 May 2026, 5:30 am
Omkar Pharmachem Board Meeting Scheduled for Q4 & FY26 Results Omkar Pharmachem Ltd. announced its Board of Directors will meet on 30th May'26 to consider and approve the audited financial results for the quarter and financial year ended 31st Mar'26. In accordance with regulations, the trading window for designated persons and their relatives remains closed until 01st Jun'26. The meeting will take place at the company's registered office at 5:00 PM.
Dear Sir/Ma''am, Please find Intimation under Reg 30 of SEBI (LODR) Regulations, 2015 for change in name of Managing Director of the company.
Others (Uncategorized) · 19 May 2026, 9:34 pm
Omkar Pharmachem Managing Director Name Change Announced Omkar Pharmachem (BSE: 532167) announced on 19th May'26 a change in the name of its Managing Director. The MD's name has been changed from Bhawani Shankar Goyal to Bhawani S Goyal. The company confirmed this is solely a name change, with no alteration to the individual's designation, role, or responsibilities within the organization. The board has formally taken note of this update.
Dear Sir, Please find Newspaper Publication regarding Special Window for Transfer & Demat of Physical Shares.
Others (Uncategorized) · 14 May 2026, 11:17 pm
Omkar Pharmachem Announces Dematerialization Window for Physical Shares Omkar Pharmachem Ltd. (BSE: 532167) has announced a special window for the transfer and dematerialization of physical shares, pursuant to a SEBI circular dated 30-Jan-26. The company published newspaper advertisements on 14-May-26 to inform shareholders. This initiative facilitates the conversion of physical share certificates into electronic form, aligning with regulatory requirements. Shareholders holding physical securities are encouraged to utilize this period to dematerialize their holdings for easier transfer and improved security.
Dear Sir/Ma''am, Please find Newspaper Publication regarding special window for transfer and dematerialization of physical shares.
Others (Uncategorized) · 25 Mar 2026, 8:02 pm
Omkar Pharmachem Opens Special Window for Physical Share Dematerialization Omkar Pharmachem (BSE: 532167) has announced a special window for the transfer and dematerialization of physical shares, effective from 05 Feb'26 to 04 Feb'27. This aligns with SEBI's circular dated 30 Jan'26. The facility is available for securities sold or purchased before 01 Apr'19. Transferred securities will be mandatorily issued in demat form and will be subject to a one-year lock-in period from the date of registration, during which they cannot be transferred or pledged. Alankit Assignments is the designated transfer agent.
Dear Sir/Ma''am, Please find additional details required for the Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015.
Others (Uncategorized) · 16 Feb 2026, 10:17 pm
Omkar Pharmachem Clarifies Delayed Disclosure on Director Cessation Omkar Pharmachem clarified the delayed disclosure regarding the cessation of Mr. Janak Raj Sharma as an Independent Director. His term, comprising two consecutive five-year periods, ended effective 12 Feb'26. The company noted the cessation at its Board Meeting on 14 Feb'26 and filed the required intimation on the same day. This resulted in a delay beyond the required 24-hour notification window. The company has expressed regret for the inadvertent delay, attributing it to a misunderstanding of regulatory filing timelines.
Dear Sir/Ma''am, Please find unaudited financial results for the quarter and nine months ended on 31.12.2025
Financial Result · 14 Feb 2026, 11:08 pm
Omkar Pharmachem Q3FY26: Net Profit Declines Amid Lower Other Income Omkar Pharmachem reported a net profit of ₹2.95 lakhs for Q3FY26, a 65.3% YoY and 41.8% QoQ decline. Total income fell to ₹10.50 lakhs from ₹13.72 lakhs YoY and ₹13.94 lakhs QoQ, driven solely by lower other income as revenue from operations was nil. Profit before tax stood at ₹3.96 lakhs, down 53.4% YoY. For the nine months ended 31st Dec'25, net profit was ₹10.68 lakhs, down 52.0% YoY. Basic EPS for the quarter was ₹0.0293 versus ₹0.0842 in Q3FY25.
Dear Sir, Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please note that the Board in their meeting held on ....
Outcome · 14 Feb 2026, 10:54 pm
Omkar Pharmachem Ltd. - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 10.5 (-22.2% YoY | -22.2% QoQ) ■ EBITDA: 4.0 (-52.0% YoY | -39.2% QoQ) ■ EBITDA Margin (%): 38.5 (-2389 bps YoY | -1078 bps QoQ) ■ PAT: 3.0 (-65.3% YoY | -41.8% QoQ) ■ EPS (INR): 0.03 (-65.2% YoY | -41.7% QoQ)
Dear Sir, Please find Report on action taken under the Special Window for re-lodgement of transfer request from 01.01.2026 to 06.01.2026
Others (Uncategorized) · 12 Feb 2026, 6:40 pm
Omkar Pharmachem Reports Nil Physical Share Transfer Requests in Special Window Omkar Pharmachem informed exchanges on 12 Feb'26 that it received zero requests for the re-lodgement of physical share transfers between 01 Jan'26 and 06 Jan'26. This was reported under the special window provided by the SEBI circular dated 02 Jul'25. The registrar, Alankit Assignments, confirmed that no requests were received, processed, approved, or rejected during this period. The disclosure indicates no pending physical share transfer issues were addressed under this specific SEBI directive for the designated timeframe.
Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Unaudited Standalone Financial ....
Intimation · 14 Feb 2026, 5:30 am
Omkar Pharmachem Board Meeting on 14th Feb'26 to Approve Q3FY26 Financial Results Omkar Pharmachem has scheduled a Board of Directors meeting on 14th Feb'26 to consider and approve its unaudited financial results for the quarter and nine months ended 31st Dec'25. In connection with this, the company's trading window for designated persons will remain closed until 16th Feb'26. The meeting is set for 04:30 P.M. at the company's registered office.
Dear Sir/Ma''am, Please find intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 w.r.t. Change in Composition of Committees of the Board and Change in the Name of Company Secretary ....
Others (Uncategorized) · 27 Jan 2026, 9:57 pm
Omkar Pharmachem Board Committee and Officer Changes Announced Omkar Pharmachem reconstituted its board committees effective 27-Jan-'26. Independent Director Anupam Kumar Mishra was appointed as a Member of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, replacing Janak Raj Sharma in all three. The filing also noted a name change for the Company Secretary & Compliance Officer from Pankaj Mahadeo Singh to Pankaj Singh, with no change in designation, role, or responsibilities. The new committee compositions are now effective.
Dear Sir, Please find Re-lodgment of transfer of shares request report for the month of December 2025 received from RTA of the company.
Others (Uncategorized) · 07 Jan 2026, 6:53 pm
Omkar Pharmachem Reports Nil Physical Share Transfer Requests for Dec'25 Omkar Pharmachem Ltd filed a report on the re-lodgement of physical share transfer requests for the month of Dec'25. The filing, dated 07 Jan'26, complies with the SEBI circular dated 02 Jul'25. The company's Registrar and Transfer Agent, Alankit Assignments, confirmed that as of 31 Dec'25, it had received, processed, approved, and rejected "NIL" requests under the special window. Consequently, the average processing time was not applicable.
Dear Sir, Please find Re-lodgment request report received from RTA of the company for the months of October and November 2025
Others (Uncategorized) · 12 Dec 2025, 11:57 pm
Omkar Pharmachem Reports Nil Physical Share Transfer Requests for Oct-Nov'25 Omkar Pharmachem Ltd. reported no requests for the re-lodgement of physical share transfers during the months of Oct'25 and Nov'25. The filing, dated 12 Dec'25, was made under the special window provided by SEBI's circular from 02 Jul'25. According to the data provided by its registrar, Alankit Assignments Ltd., zero requests were received, processed, approved, or rejected during this two-month period, indicating no activity under this specific compliance requirement for physical securities.